A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Tivantinib (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 17 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 10 Jun 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.
- 05 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.